Q-Med's Durolane Knee Therapy, DePuy's CoMplete Hip Go To Panel
This article was originally published in The Gray Sheet
Executive Summary
FDA's Orthopedic and Rehabilitation Devices panel will meet Aug. 19 to assess Q-Med's PMA application for its Durolane single-injection, hyaluronic acid-based treatment for knee osteoarthritis
You may also be interested in...
FDA Panel Endorses Genzyme’s Synvisc-One Knee Therapy
FDA's Orthopedic and Rehabilitation Devices advisory panel voted unanimously last week to recommend approval of Genzyme's PMA supplement for a single-dose version of its hyaluronic acid-based osteoarthritis knee therapy
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.